IP Library Granted Patent US 7,253,185
Granted Patent B2
US 7,253,185 · App. 11/119,541 · Granted Aug 7, 2007

Amino ceramide-like compounds and therapeutic methods of use

Assignees: The Regents of the University of Michigan; Genzyme Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,253,185
App. No.
11/119,541
Granted
Aug 7, 2007
Kind
B2
Abstract

The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

Claims (14)

1. A pharmaceutical composition comprising a compound represented by the following structural formula:

or a stereoisomer, a pharmaceutically acceptable salt or a mixture thereof; and

a pharmaceutically acceptable carrier or an excipient, wherein:

R 1 is a phenyl, a substituted phenyl group, a branched aliphatic group, or a 7-15 carbons long alkyl chain or a 7-15 carbons long alkenyl chain with a double bond next to the kernel;

R 2 is an alkyl group 6, 7, or 8 carbons long; and

R 3 is a pyrrolidine, azetidine or piperidine, in which the nitrogen atom is attached to the kernel.

2. The pharmaceutical composition of claim 1 , wherein R 1 is a phenyl group substituted with a functional group selected from the group consisting of a p-methoxy, hydroxyl, methylenedioxy, ethylenedioxy, trimethylenedioxy and cyclohexyl.

3. A pharmaceutical composition comprising a compound represented by the structural formula:

or a stereoisomer, a pharmaceutically acceptable salt or a mixture thereof; and

a pharmaceutically acceptable carrier or an excipient, wherein:

R 1 is a substituted or unsubstituted phenyl group, a branched aliphatic group, or a 7-15 carbons long alkyl chain or a 7-15 carbons long alkenyl chain with a double bond next to the kernel;

R 2 is an alkyl group 6, 7, or 8 carbons long; and

R 3 is pyrrolidine, in which the nitrogen atom is attached to the kernel.

4. The pharmaceutical composition of claim 3 , wherein R 1 is a phenyl group substituted with a functional group selected from the group consisting of a p-methoxy, hydroxyl, methylenedioxy, ethylenedioxy, trimethylenedioxy and cyclohexyl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2018
From: SHAYMAN, JAMES A
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 047500/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2018
From: HARRIS, DAVID J; SIEGEL, CRAIG; NELSON, CAROL A; COPELAND, DIANE P
To: GENZYME CORPORATION
Reel/Frame 047500/0364 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Sep 17, 2008
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021544/0112 →
Continuity (3)
Continuation 1083949700 · May 5, 2004
Continuation 1013431500 · Apr 29, 2002
Related Publication 20050267094A1 · Dec 1, 2005